Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1219 ARTÍCULOS , VIENDO DEL 571 AL 585

Late Onset Alzheimer's Disease: Novel Clinical Prospects for the Future

Maiese K.

Curr Neurovasc Res. 2017;14(2):89. doi: 10.2174/1567202614999170313155128.

Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease

Reeves S, McLachlan E, Bertrand J, D'Antonio F, Brownings S, Nair A, Greaves S, Smith A, Taylor D, Dunn J, Marsden P, Kessler R, Howard R.

Brain. 2017 Apr 1;140(4):1117-1127. doi: 10.1093/brain/aww359.

Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR Jr, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2017 Apr;13(4):e1-e85. doi: 10.1016/j.jalz.2016.11.007. Epub 2017 Mar 22.

Diagnostic and Prognostic Potential of Retinal Biomarkers in Early On-Set Alzheimer's Disease

Shariflou S, Georgevsky D, Mansour H, Rezaeian M, Hosseini N, Gani F, Gupta V, Braidy N, Golzan SM.

Curr Alzheimer Res. 2017;14(9):1000-1007. doi: 10.2174/1567205014666170329114445.

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials

Fleisher AS, Joshi AD, Sundell KL, Chen YF, Kollack-Walker S, Lu M, Chen S, Devous MD Sr, Seibyl J, Marek K, Siemers ER, Mintun MA.

Alzheimers Dement. 2017 Oct;13(10):1117-1124. doi: 10.1016/j.jalz.2017.02.009. Epub 2017 Mar 30.

Does Functional Connectivity Provide a Marker for Cognitive Rehabilitation Effects in Alzheimer's Disease? An Interventional Study

Ochmann S, Dyrba M, Grothe MJ, Kasper E, Webel S, Hauenstein K, Teipel SJ.

J Alzheimers Dis. 2017;57(4):1303-1313. doi: 10.3233/JAD-160773.

Currents of memory: recent progress, translational challenges, and ethical considerations in fornix deep brain stimulation trials for Alzheimer's disease

Viaña JNM, Vickers JC, Cook MJ, Gilbert F.

Neurobiol Aging. 2017 Aug;56:202-210. doi: 10.1016/j.neurobiolaging.2017.03.001. Epub 2017 Mar 11.

Graph Theory and Brain Connectivity in Alzheimer's Disease

delEtoile J, Adeli H.

Neuroscientist. 2017 Dec;23(6):616-626. doi: 10.1177/1073858417702621. Epub 2017 Apr 13.

Alzheimer Disease: Monotherapy vs. Combination Therapy

Lawler E, Avila A.

Am Fam Physician. 2017 Apr 1;95(7):452.

Early-Onset Alzheimer Disease

Mendez MF.

Neurol Clin. 2017 May;35(2):263-281. doi: 10.1016/j.ncl.2017.01.005.

Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer's disease: a Phase II multicenter randomised controlled trial

Xiao S, Wang T, Ma X, Qin Y, Li X, Zhao Z, Liu X, Wang X, Xie H, Jiang Q, Sun L, Luo B, Shang L, Chen W, Bai Y, Tang M, He M, Wu L, Ma Q, Hou D, He J.

Age Ageing. 2017 Sep 1;46(5):767-773. doi: 10.1093/ageing/afx045.

Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis

Bagyinszky E, Giau VV, Shim K, Suk K, An SSA, Kim S.

J Neurol Sci. 2017 May 15;376:242-254. doi: 10.1016/j.jns.2017.03.031. Epub 2017 Mar 22.

Regulatory effects of galanin system on development of several age-related chronic diseases

Fang P, Yu M, Wan D, Zhang L, Han L, Shen Z, Shi M, Zhu Y, Zhang Z, Bo P.

Exp Gerontol. 2017 Sep;95:88-97. doi: 10.1016/j.exger.2017.04.009. Epub 2017 Apr 25.

Reversible Pisa Syndrome Induced by Rivastigmine in a Patient With Early-Onset Alzheimer Disease

Hsu CW, Lee Y, Lee CY, Lin PY.

Clin Neuropharmacol. 2017 May/Jun;40(3):147-148. doi: 10.1097/WNF.0000000000000215.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias